Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer.

Oxidative stress caused by an increase in reactive oxygen species levels or a decrease in cellular antioxidant capacity can evoke the modulation of various cellular events including androgen receptor (AR) signaling via direct or indirect interactions. In this review, we summarize the mechanisms of AR activation by oxidative stress including: i) AR overexpression; ii) AR activation by AR co-regulators or intracellular signal transduction pathways; iii) generation of AR mutations or splice variants; and iv) de novo androgen synthesis. AR signaling augmented by oxidative stress appears to contribute to pro-survival and anti-apoptotic effects in prostate cancer cells in response to androgen deprivation therapy. In addition, AR signaling suppresses anti-survival and pro-apoptotic effects in prostate cancer cells in response to various cytotoxic and tumor-suppressive interventions including taxanes and radiation through the modulation of βIII-tubulin and ataxia telangiectasia-mutated kinase expression respectively. Taken together, AR signaling appears to render prostate cancer cells refractory to various therapeutic interventions including castration, taxanes, and radiation, indicating that AR signaling is a comprehensive resistant factor and crucial target for prostate cancer treatment.

[1]  E. Martinelli,et al.  Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer , 2012, Clinical Cancer Research.

[2]  M. Parker,et al.  Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression , 2008, Oncogene.

[3]  E. Hurt,et al.  Effects of Manganese Superoxide Dismutase Silencing on Androgen Receptor Function and Gene Regulation: Implications for Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[4]  M. Gleave,et al.  Dysregulation of Sterol Response Element-Binding Proteins and Downstream Effectors in Prostate Cancer during Progression to Androgen Independence , 2004, Cancer Research.

[5]  S. Yeh,et al.  Identification of 3',5'-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. , 1994, Molecular endocrinology.

[6]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[7]  N. Sharifi,et al.  SOD Mimetics: A Novel Class of Androgen Receptor Inhibitors That Suppresses Castration-Resistant Growth of Prostate Cancer , 2011, Molecular Cancer Therapeutics.

[8]  Yuet-Kin Leung,et al.  Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. , 2003, The American journal of pathology.

[9]  C. Bevan,et al.  The Role of Androgen Receptor Mutations in Prostate Cancer Progression , 2009, Current genomics.

[10]  K. Kuroiwa,et al.  Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. , 2012, The Journal of urology.

[11]  G. Wilding,et al.  Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. , 1997, Journal of the National Cancer Institute.

[12]  Huiqing Yuan,et al.  Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. , 2005, Carcinogenesis.

[13]  B. Wilson,et al.  Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. , 2007, Neoplasia.

[14]  K. Kuroiwa,et al.  Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells , 2011, The Prostate.

[15]  T. Nishiyama Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  J. Andersen,et al.  Oxidative stress in neurodegeneration: cause or consequence? , 2004, Nature Reviews Neuroscience.

[17]  Geun-Young Kim,et al.  Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression. , 2012, Biochemical and biophysical research communications.

[18]  Peng Huang,et al.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? , 2009, Nature Reviews Drug Discovery.

[19]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[20]  K. Tomer,et al.  Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[21]  T. Uchiumi,et al.  Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression , 2010, Oncogene.

[22]  Ricky A. Sharma,et al.  Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. , 2008, Cancer letters.

[23]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Robison,et al.  The role of oxidative stress in prostate cancer , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[25]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[26]  H. Izumi,et al.  Twist and p53 reciprocally regulate target genes via direct interaction , 2008, Oncogene.

[27]  M. Gleave,et al.  Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer , 2005, Clinical Cancer Research.

[28]  P. Ray,et al.  Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. , 2012, Cellular signalling.

[29]  K. Chi,et al.  Beyond Castration—Defining Future Directions in the Hormonal Treatment of Prostate Cancer , 2012, Hormones and Cancer.

[30]  M. Zelefsky Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial , 2006 .

[31]  M. Kattan,et al.  Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  小川 和彦 What's going on 放射線 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. JAMA. 2004;292:821-7. PMID:15315996--放射線治療 , 2005 .

[33]  C. Pham,et al.  Upregulation of Twist-1 by NF-κB Blocks Cytotoxicity Induced by Chemotherapeutic Drugs , 2007, Molecular and Cellular Biology.

[34]  T. Ratliff High molecular mass proteome of androgen-independent prostate cancer. , 2005, Journal of Urology.

[35]  Endothelin‐1 enhances the expression of the androgen receptor via activation of the c‐myc pathway in prostate cancer cells , 2009, Molecular carcinogenesis.

[36]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[37]  L. Chung,et al.  Activation of Androgen Receptor, Lipogenesis, and Oxidative Stress Converged by SREBP-1 Is Responsible for Regulating Growth and Progression of Prostate Cancer Cells , 2011, Molecular Cancer Research.

[38]  Rocío Martín,et al.  Quantitative and immunohistochemical evaluation of PCNA, androgen receptors, apoptosis, and Glutathione‐S‐Transferase P1 on preneoplastic changes induced by cadmium and zinc chloride in the rat ventral prostate , 2005, The Prostate.

[39]  Christopher U. Jones,et al.  Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.

[40]  M. Shiota,et al.  Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. , 2011, Journal of molecular endocrinology.

[41]  D. Coppola,et al.  Ack1-mediated Androgen Receptor Phosphorylation Modulates Radiation Resistance in Castration-resistant Prostate Cancer* , 2012, The Journal of Biological Chemistry.

[42]  S. Kato,et al.  Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. , 2010, Molecular endocrinology.

[43]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[44]  A. Ravaud,et al.  A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. , 2012, European journal of cancer.

[45]  Masataka Nakamura,et al.  Unique CCT repeats mediate transcription of the TWIST1 gene in mesenchymal cell lines. , 2007, Biochemical and biophysical research communications.

[46]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[47]  H. Izumi,et al.  Twist promotes tumor cell growth through YB-1 expression. , 2008, Cancer research.

[48]  M. Landström,et al.  Combined castration and fractionated radiotherapy in an experimental prostatic adenocarcinoma. , 1997, International journal of radiation oncology, biology, physics.

[49]  B. Djavan,et al.  Androgen deprivation therapy. , 2008, Reviews in urology.

[50]  Yi Lu,et al.  Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. , 2006, Cancer research.

[51]  Xu Wang,et al.  Long-term mequindox treatment induced endocrine and reproductive toxicity via oxidative stress in male Wistar rats. , 2011, Toxicology and applied pharmacology.

[52]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[53]  C. Woo,et al.  Role of the BLT2, a leukotriene B4 receptor, in Ras transformation , 2004, Oncogene.

[54]  J. Ni,et al.  Induction of Androgen Receptor Expression by Phosphatidylinositol 3-Kinase/Akt Downstream Substrate, FOXO3a, and Their Roles in Apoptosis of LNCaP Prostate Cancer Cells* , 2005, Journal of Biological Chemistry.

[55]  P. Light,et al.  Reactive oxygen species directly modify sodium-calcium exchanger activity in a splice variant-dependent manner. , 2009, Journal of molecular and cellular cardiology.

[56]  R. Touyz,et al.  Redox signaling in hypertension. , 2006, Cardiovascular research.

[57]  J. Kumar,et al.  Activation of a non-genomic Pim-1/Bad-Pser75 module is required for an efficient pro-survival effect of Bcl-xL induced by androgen in LNCaP cells. , 2011, The international journal of biochemistry & cell biology.

[58]  S. Egawa,et al.  High molecular mass proteome of androgen‐independent prostate cancer , 2005, Proteomics.

[59]  S. Koul,et al.  Oxidative stress in prostate cancer. , 2009, Cancer letters.

[60]  M. Shiota,et al.  Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. , 2011, Current cancer drug targets.

[61]  Goedele Roos,et al.  Protein sulfenic acid formation: from cellular damage to redox regulation. , 2011, Free radical biology & medicine.

[62]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[63]  P N Leigh,et al.  Androgen‐induced up‐regulation of tubulin isoforms in neuroblastoma cells , 2001, Journal of neurochemistry.

[64]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[65]  C. D’Este,et al.  Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. , 2005, The Lancet. Oncology.

[66]  K Botzenhart,et al.  Reactive Oxygen Species , 2014 .

[67]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[68]  M. Kattan,et al.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. , 2001, Urology.

[69]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[70]  Haishan Xu,et al.  ENaC alpha-subunit variants are expressed in lung epithelial cells and are suppressed by oxidative stress. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[71]  K. Kuroiwa,et al.  Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. , 2011, Endocrine-related cancer.

[72]  Jung-A Choi,et al.  Pro-survival of estrogen receptor-negative breast cancer cells is regulated by a BLT2-reactive oxygen species-linked signaling pathway. , 2010, Carcinogenesis.

[73]  J. Mayo,et al.  Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells , 2009, International journal of cancer.

[74]  N. Socci,et al.  Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.

[75]  A. Hanlon,et al.  Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. , 2003, International journal of radiation oncology, biology, physics.

[76]  H. Friess,et al.  BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation , 2008, British Journal of Cancer.

[77]  T. Kawai,et al.  Oxidative stress-induced alternative splicing of transformer 2beta (SFRS10) and CD44 pre-mRNAs in gastric epithelial cells. , 2009, American journal of physiology. Cell physiology.

[78]  D. Tindall,et al.  Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. , 2007, Endocrine reviews.

[79]  D. Tindall,et al.  Androgen Action in Prostate Cancer , 2009, Hormones & cancer.

[80]  R. Ge,et al.  Mono-(2-ethylhexyl) phthalate affects the steroidogenesis in rat Leydig cells through provoking ROS perturbation. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[81]  Seiji Naito,et al.  Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. , 2009, Cancer research.

[82]  L. Chung,et al.  Reactive oxygen species mediate androgen receptor‐ and serum starvation‐elicited downstream signaling of ADAM9 expression in human prostate cancer cells , 2007, The Prostate.

[83]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[84]  W. Gerald,et al.  NF-kappaB regulates androgen receptor expression and prostate cancer growth. , 2009, The American journal of pathology.

[85]  E. Suzuki,et al.  Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. , 2011, The Journal of urology.

[86]  Miao-Fen Chen,et al.  The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. , 2007, Endocrine-related cancer.

[87]  R. Ricks Radiation response. , 1989, Emergency.

[88]  Seiji Naito,et al.  Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. , 2011, Free radical biology & medicine.

[89]  R. Zhao,et al.  Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. , 2010, Free radical biology & medicine.

[90]  C. D’Este,et al.  Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. , 2011, The Lancet. Oncology.

[91]  K. Burnstein,et al.  Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. , 1999, Molecular endocrinology.

[92]  D. Bostwick,et al.  Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer , 2000, Cancer.

[93]  A. Abdel‐Mageed,et al.  Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species , 2010, Experimental biology and medicine.

[94]  J. Trapman,et al.  Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. , 1993, The Journal of biological chemistry.

[95]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[96]  D. Mackenzie,et al.  The curcumin analog ca27 down‐regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells , 2012, The Prostate.

[97]  Desok Kim,et al.  Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.

[98]  T. Uchiumi,et al.  Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. , 2011, Free radical biology & medicine.

[99]  D. Piscitelli,et al.  Identification of 3',5'-cyclic adenosine monophosphate-inducible nuclear factors binding to the human urokinase promoter in mouse Sertoli cells. , 1993, Molecular endocrinology.

[100]  L. Chung,et al.  Androgen Receptor Survival Signaling Is Blocked by Anti-β2-microglobulin Monoclonal Antibody via a MAPK/Lipogenic Pathway in Human Prostate Cancer Cells* , 2010, The Journal of Biological Chemistry.

[101]  S. Pang,et al.  Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. , 2002, Endocrinology.

[102]  E. Messing,et al.  Androgen deprivation therapy for prostate cancer: Current status and future prospects , 2004, The Prostate.

[103]  Y. Sasaguri,et al.  Programmed Cell Death Protein 4 Down-regulates Y-Box Binding Protein-1 Expression via a Direct Interaction with Twist 1 to Suppress Cancer Cell Growth , 2009 .

[104]  B. Yankner,et al.  The aging stress response. , 2010, Molecular cell.

[105]  H. Uramoto,et al.  p73 Interacts with c-Myc to Regulate Y-box-binding Protein-1 Expression* , 2002, The Journal of Biological Chemistry.

[106]  A. Acharya,et al.  Redox regulation in cancer , 2010, Oxidative medicine and cellular longevity.

[107]  E. Bruckheimer,et al.  TGF‐β signaling and androgen receptor status determine apoptotic cross‐talk in human prostate cancer cells , 2008, The Prostate.

[108]  Yajun Yi,et al.  Molecular Alterations in Primary Prostate Cancer after Androgen Ablation Therapy , 2005, Clinical Cancer Research.

[109]  T. Triche,et al.  Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. , 2009, Cancer cell.

[110]  A. Gao,et al.  Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  E. Sato,et al.  [Reactive oxygen]. , 2002, Nihon eiseigaku zasshi. Japanese journal of hygiene.

[112]  A. Zietman,et al.  Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. , 1997, International journal of radiation oncology, biology, physics.

[113]  D. Tindall,et al.  Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.

[114]  S. Balk Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Castration-Recurrent Prostate Cancer , 2009 .